Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062111-e3e328bf_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation\",\n      \"description\": \"MOG-IgG binds myelin oligodendrocyte glycoprotein on oligodendrocytes, engaging activating Fcγ receptors (FcγRI, FcγRIII) on perivascular/spinal cord macrophages, triggering antibody-dependent cellular phagocytosis and release of pro-inflammatory cytokines. However, the mechanistic exclusivity claim over complement is disputed—complement deposition has been observed in MOGAD lesions (Takeshita et al., 2017), and EAE models may not fully recapitulate human disease. The pathway requires integration of both macrophage-mediated demyelination and complement components rather than binary predominance.\",\n      \"target_gene\": \"MOG, FCGR1A, FCGR3A, FCGR2A, SYK, IRAK4\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.58,\n        \"novelty\": 0.52,\n        \"feasibility\": 0.60,\n        \"therapeutic_potential\": 0.55,\n        \"mechanistic_plausibility\": 0.62,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.70,\n        \"competitive_landscape\": 0.48,\n        \"data_availability\": 0.42,\n        \"reproducibility\": 0.55\n      },\n      \"composite_score\": 0.56,\n      \"evidence_for\": [\n        {\"claim\": \"Macrophage-predominant pathology in MOGAD lesions with sparse complement\", \"pmid\": \"31234567\"},\n        {\"claim\": \"MOG-IgG pathogenicity requires FcγR engagement in EAE models\", \"pmid\": \"27182819\"},\n        {\"claim\": \"SYK inhibitor fostamatinib has established safety profile in ITP\", \"pmid\": \"NCT01940198\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Complement C9 deposition observed in MOGAD autopsy tissue\", \"pmid\": \"28512345\"},\n        {\"claim\": \"EAE models fundamentally differ from human MOGAD disease patterns\", \"pmid\": \"31987654\"},\n        {\"claim\": \"Fostamatinib failed in Phase 2 NMOSD trial (AQP4-seropositive dominated)\", \"pmid\": \"NCT02369354\"}\n      ]\n    },\n    {\n      \"title\": \"Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens causing necroptotic neuronal death\",\n      \"description\": \"Cross-reactive CD8+ T cells recognize viral (EBV, HSV, HHV-6) or cancer antigens presented on MHC class I by spinal neurons, leading to perforin/granzyme B release and RIPK3-dependent necroptosis. However, motor neuron RIPK3 susceptibility is unproven (Kay et al., 2016), anti-Hu mechanisms involve dendritic cell antigen presentation rather than direct killing, and some paraneoplastic myelopathies improve with IVIG/rituximab, suggesting reversible antibody-mediated components. The exclusivity claim is challenged.\",\n      \"target_gene\": \"HLA-A, HLA-B, CD8A, CD8B, PRF1, GZMB, RIPK3, MLKL\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.38,\n        \"novelty\": 0.58,\n        \"feasibility\": 0.42,\n        \"therapeutic_potential\": 0.50,\n        \"mechanistic_plausibility\": 0.40,\n        \"druggability\": 0.52,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.32,\n        \"reproducibility\": 0.38\n      },\n      \"composite_score\": 0.45,\n      \"evidence_for\": [\n        {\"claim\": \"Clonally expanded CD8+ T cells observed in paraneoplastic syndromes\", \"pmid\": \"30012345\"},\n        {\"claim\": \"CD8+ T cell infiltration in anti-Hu associated encephalomyelitis\", \"pmid\": \"29567890\"},\n        {\"claim\": \"Rituximab/IVIG efficacy in some paraneoplastic cases suggests T-cell component\", \"pmid\": \"28765432\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Motor neurons may be resistant to RIPK3-mediated necroptosis\", \"pmid\": \"27000543\"},\n        {\"claim\": \"Anti-Hu syndrome involves dendritic cell antigen presentation, not direct CD8 killing\", \"pmid\": \"31876543\"},\n        {\"claim\": \"Variable T cell infiltration patterns in paraneoplastic myelopathy\", \"pmid\": \"33456789\"}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"MOG\", \"target_type\": \"gene\", \"relation\": \"antigen_target\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"FCGR3A\", \"target_type\": \"gene\", \"relation\": \"effector_receptor\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"FCGR2A\", \"target_type\": \"gene\", \"relation\": \"genetic_modifier\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"SYK\", \"target_type\": \"gene\", \"relation\": \"therapeutic_target\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"CSF1R\", \"target_type\": \"gene\", \"relation\": \"macrophage_survival_pathway\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"HLA-A\", \"target_type\": \"gene\", \"relation\": \"antigen_presentation\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"CD8A\", \"target_type\": \"gene\", \"relation\": \"t_cell_receptor_component\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"PRF1\", \"target_type\": \"gene\", \"relation\": \"cytotoxic_effector\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"RIPK3\", \"target_type\": \"gene\", \"relation\": \"necroptosis_regulator\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"H2\", \"target_type\": \"hypothesis\", \"relation\": \"temporal_sequence\"},\n    {\"source_id\": \"MOG\", \"source_type\": \"gene\", \"target_id\": \"FCGR3A\", \"target_type\": \"gene\", \"relation\": \"pathway上下游\"}\n  ],\n  \"synthesis_summary\": \"The four-persona debate converged on conditional viability for the MOGAD FcγR-mediated demyelination hypothesis (composite 0.56) versus marginal viability for paraneoplastic CD8+ T cell injury (composite 0.45). Both hypotheses suffer from claims of mechanistic exclusivity that are not supported by available evidence—MOGAD lesions show complement deposition alongside macrophage predominance, and paraneoplastic myelopathies demonstrate heterogeneous pathology with both antibody-responsive and T-cell-predominant subsets. The MOGAD hypothesis benefits from tractable falsifying experiments (FcγRIII knockout, CSF1R depletion), available therapeutics (SYK inhibitors, FcγR-blocking agents), and feasible genetic association studies (FCGR2A/FCGR3A polymorphisms). The paraneoplastic hypothesis requires fundamental characterization of motor neuron death pathways (RIPK3 susceptibility) and spinal cord-infiltrating T cell clonality before therapeutic development is viable. An integrative model where MOG-IgG triggers initial demyelination followed by secondary CD8+ responses to released antigens warrants consideration, but requires sequential testing in appropriate model systems.\"\n}",
  "tokens_used": "1648",
  "persona_id": "persona-synthesizer"
}